Skip to content

    Anupam Rasayan India Q1 FY27 earnings call

    ANURAS
    Chemicals·14 Aug 2026
    Management Summary

    Anupam Rasayan India Limited reported a strong start to FY27 with consolidated total income growing 36% year-on-year, driven by new product commercialization and robust demand. The company achieved a global first by commercializing ETFA using flow chemistry and saw significant contributions from the Jayhawk acquisition. While EBITDA margins remained healthy, PAT growth was tempered by higher depreciation. The acquisition of Bliss GVS Pharma is on track, further strengthening the company's integrated pharmaceutical platform.

    Highlights

    6

    • Strong revenue growth of 36% YoY for Q1 FY27, reaching INR667.5 crores.

    • EBITDA grew 35% YoY to INR174.9 crores, with healthy margins maintained at 26%.

    • Successful commercialization of ETFA via flow chemistry, demonstrating advanced R&D capabilities.

    • Secured a Letter of Intent with BASQUEVOLT for a potential USD300 million long-term supply contract over 10 years.

    • Jayhawk acquisition is integrating well, contributing 20-22% of revenue and 19-20% EBITDA margin in Q1 FY27.

    • Bliss GVS Pharma acquisition is progressing as planned, expected to conclude by mid-September.

    Concerns

    2

    • PAT growth at 6% YoY (INR51.2 crores) significantly lagged EBITDA growth (35%), primarily due to increased depreciation from asset base expansion and Jayhawk.

    • Ex-Jayhawk, standalone revenue growth would have been single-digit for the quarter.

    Key financials

    Single quarter

    06 metrics
    1. 01Consolidated Total Income₹667.5 Cr+36%YoY
    2. 02Consolidated EBITDA₹174.9 Cr+35%YoY
    3. 03Consolidated EBITDA Margin26%
    4. 04Consolidated PAT₹51.2 Cr+6%YoY
    5. 05Consolidated PAT Margin8%

    Segment breakdown

    Jayhawk Fine Chemicals
    ₹145 Cr Revenue Contribution₹30 Cr EBITDA Contribution19% EBITDA Margin
    Polymer Business (Standalone)
    20% Share of Business
    Polymer Business (Consolidated)
    30% Share of Business
    List

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    ₹70 crores

    Debt

    Debt disclosed

    M&A

    Jayhawk Fine Chemicals

    acquisition · integrated

    M&A

    Bliss GVS Pharma

    acquisition · pending regulatory

    Liquidity

    Liquidity disclosed

    Working capital remained largely stable during the quarter, with expectations for further improvement in FY27. Bliss GVS Pharma has cash flow of over INR200 crores and a healthy balance sheet with no debt, suggesting internal accruals could fund future API asset acquisitions.

    Guidance & targets

    15
    CategoryTargetPriority
    Profitability
    Consolidated EBITDA Margin
    22-24%
    		High
    Profitability
    Standalone EBITDA Margin
    24-26%
    		High
    Product Mix
    Polymer Business Share (Standalone)
    20-25%
    		High
    Product Mix
    Polymer Business Share (Consolidated)
    30-35%
    		High
    Market Opportunity
    ETFA Market Size
    USD0.5 billion
    		High
    Capex
    Standalone Capex
    INR70-80 crores
    		High
    Capacity Utilization
    Bliss GVS Pharma Capacity Utilization
    60-70%
    		High
    Revenue Growth
    Organic Revenue Growth (ex-Jayhawk)
    23-27%
    		Medium
    Revenue Growth
    Jayhawk Additional Revenue Growth
    10-15%
    		High
    Commercialization
    BASQUEVOLT LOI Commercialization Start
    Begin during FY27
    		High
    Commercialization
    BASQUEVOLT LOI Revenue Ramp-up
    Larger revenue in 2-3 years
    		High
    Long-term Contracts
    BASQUEVOLT LOI Potential Value
    USD300 million
    		High
    Long-term Contracts
    Cumulative LOI and Contracts Potential Value
    INR18,000 crores
    		High
    Order Book Contribution
    Order Book Contribution to Revenue
    ~25%
    		High
    Order Book Contribution
    Order Book Contribution to Revenue
    ~30%
    		High

    What to watch in Q2 FY27

    5

    Bliss GVS Pharma Acquisition Conclusion

    First half of September
    CurrentSEBI approval received, open offer concluded
    TargetTransaction fully concluded

    Why it matters

    Marks a transformational step for Anupam's pharmaceutical platform and integration efforts.

    We expect that by the first half of September, we should be able to conclude this transaction fully.

    Risks & concerns

    2
    RiskSeverity

    PAT Growth Lagging EBITDA

    PAT growth of 6% YoY significantly lagged EBITDA growth of 35% due to increased depreciation from asset base expansion and Jayhawk's different depreciation policies. — Management acknowledged

    medium

    Agrochemical Demand Cyclicality

    Lesser contribution from the agrochemical segment this quarter due to the demand cycle, though management expects the business to remain stable with its own growth path. — Management acknowledged

    low

    Q&A highlights

    8

    “So we continue to explore that. And right now, there is nothing specifically that is there that we need to share, but we continue to explore. And once the Bliss acquisition is also consummated, we will be working with the Bliss management to explore any acquisitions together.”

    Analyst sought clarity on a previously mentioned strategic initiative, and management indicated it's still exploratory and contingent on the Bliss acquisition.

    asked by Sujal

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Performance & Diversification

    Anupam Rasayan commenced FY27 with robust performance, achieving a 36% year-on-year growth in consolidated total income to INR667.5 crores. Consolidated EBITDA also saw a 35% increase to INR174.9 crores, maintaining healthy margins at 26%. This growth reflects continued momentum and a strategic shift towards a more diversified specialty chemicals platform, expanding into pharmaceuticals, performance materials, electronics, and EV applications.

    02

    Pioneering Flow Chemistry & New Product Commercialization

    A significant highlight of the quarter was the commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry, marking Anupam Rasayan as the first company globally to achieve this. This underscores the company's strong R&D and process engineering capabilities in complex fluorination chemistry. Additionally, the company commercialized one new product in pharmaceuticals and two new products in performance materials, further broadening its high-value portfolio.

    03

    Strategic Acquisitions and Integration Progress

    The Jayhawk Fine Chemicals acquisition is proving strategic, contributing approximately INR145 crores in revenue (20-22% of total) and INR30 crores in EBITDA (19-20% margin) in Q1 FY27. This acquisition provides a US manufacturing base and strengthens capabilities in advanced chemistries for high-value markets like semiconductors. The proposed acquisition of Bliss GVS Pharma is progressing as planned, with the transaction expected to conclude by the first half of September, aiming to create an integrated pharmaceutical platform.

    04

    Long-term Growth Opportunities & Pipeline

    Anupam Rasayan secured a Letter of Intent with BASQUEVOLT for a potential USD300 million long-term supply of a specialty chemical product over 10 years, with commercialization expected to begin in FY27. The company's cumulative signed LOIs and contracts represent roughly INR18,000 crores of potential business. The R&D pipeline remains strong with over 65 pharma and polymer molecules, and a target to improve Bliss GVS Pharma's capacity utilization from 30% to 60-70% over 2-3 years.

    05

    Capital Allocation and Financial Discipline

    The company has completed its major capex cycle, with no significant capex planned for the existing Anupam platform in the near term, projecting INR70-80 crores for standalone capex in FY27/FY28 for maintenance and repurposing. While PAT growth at 6% lagged EBITDA growth due to increased depreciation from asset base expansion and Jayhawk, cash profit for Q1 FY27 stood at INR64 crores. The Bliss GVS Pharma acquisition will be funded by INR300 crores of debt and an equity-linked instrument, with Bliss's healthy balance sheet and internal accruals expected to support future API asset acquisitions.

    This is an AI-generated summary of a publicly available earnings call transcript.